Skip to main content
See every side of every news story
Published loading...Updated

Biocon Chair Kiran Mazumdar-Shaw Charts Five-Year Succession ...

Mazumdar-Shaw said the transition will move step by step from director to vice-chair and eventually chair, while she keeps a 29.92% stake.

  • On Tuesday, Biocon Ltd Chairman and Managing Director Kiran Mazumdar-Shaw announced a phased five-year leadership transition plan, naming her niece Claire Mazumdar as the eventual successor to the chair position.
  • Founded in a Bengaluru garage in 1978, Biocon has grown into a leading biosimilars manufacturer with a market capitalization of $6.14 billion and a portfolio of more than 30 biosimilars in development or commercial use.
  • Claire, 37, currently serves as founding chief executive of Bicara Therapeutics, an oncology-focused biotech firm. She previously led business development at Rheos Medicines and focused on company formation at Third Rock Ventures.
  • Mazumdar-Shaw stated she wants to ensure the 'family legacy continues,' noting Claire is 'very aligned' with her strategic vision. The transition will proceed step-by-step from director to vice-chair and eventually chair.
  • Fortune India first reported the succession strategy, which aims to secure leadership stability as Biocon continues deriving significant revenue from the United States and Europe markets.
Insights by Ground AI

24 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 45% of the sources lean Right
45% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Times of India broke the news in India on Tuesday, May 5, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal